EGFR and neoplasm: Silencing B7‐H4 can reverse the inhibition of CD8+ T‐cell function and block the tumor immune escape.[338] In summary, tumor cells reduce their chances of being recognized and killed by CD8+ T cells and decrease the infiltration and cytotoxicity of CD8+ T cells through the EGFR signaling pathway, thereby weakening the effectiveness of immunotherapy.